# Brand vs Generic Market Share
## HHS-2024-0108
_[Department of Health and Human Services](../3_agency/Department of Health and Human Services.md)_ (HHS) / CMS


+ **The topic area that most closely aligns with the AI use case**: Health & Medical
+ **Whether the use case is implemented solely with the commercial-off-the-shelf or freely available AI products identified in Appendix B**: None of the above.
+ **Description of the AI’s intended purpose, including: (1) what problem the AI is used to solve and (2) the expected benefits and positive outcomes from the AI for an agency’s mission and/or the general public**: The Drug Data Processing System (DDPS) needs to predict changes in Medicare Part D costs 

Understanding beneficiary changes from Brand to Generic drugs allows for more accurate financial estimates.
+ **Description of what the AI system outputs, whether it’s a prediction, recommendation, decision, etc**: Analyze generic drugs compared to brand drugs over time and forecast future market shares based on Part D claims volume
+ **The current stage of System Development Life Cycle (SDLC) for the AI use case (See System Development Life Cycle (SDLC) - Glossary | NIST CSRC)**: Initiated
+ **Whether the AI use case is rights-impacting or safety-impacting, as defined in Section 6 of OMB Memorandum M-24-10. Note also that Appendix I of that memorandum lists categories of use cases that are presumed by default to impact rights and safety. If your use case falls into those lists, you must not answer “neither” to this question without a formal determination made by your agency’s Chief AI Officer, pursuant to Section 5(b) of OMB Memorandum M-24-10**: Neither
+ **Date when the AI use case’s purpose and high-level requirements were first defined**: 10/1/2021